Showing results (41-50 of 93) with videos related to
Sort By:
Pageof 10
Infectious Agents and Cancer|July 14, 2007
Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young womenRalph P Insinga, Erik J Dasbach, Elamin H Elbasha, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 10, 2007
Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectivesRalph P Insinga, Erik J Dasbach, Elamin H Elbasha, et al.Cancer|August 23, 2008
Risk of subsequent endometrial carcinoma associated with endometrial intraepithelial neoplasia classification of endometrial biopsiesJames V Lacey, George L Mutter, Marisa R Nucci, et al.International Journal of Cancer|February 1, 2012
Incidence rates of endometrial hyperplasia, endometrial cancer and hysterectomy from 1980 to 2003 within a large prepaid health planJames V Lacey, Victoria M Chia, Brenda B Rush, et al.Cancer Research|July 18, 2008
PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinomaJames V Lacey, George L Mutter, Brigitte M Ronnett, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2008
Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic EvaluationRalph P Insinga, Erik J Dasbach, Shannon E Allen, et al.Vaccine|December 7, 2007
Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluationRalph P Insinga, Erik J Dasbach, Elamin H Elbasha, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 10, 2009
Human papillomavirus infections and vulvar disease developmentSuzanne M Garland, Ralph P Insinga, Heather L Sings, et al.Journal of Medical Economics|September 7, 2018
Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the USRalph P Insinga, David J Vanness, Josephine L Feliciano, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 24, 2011
A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort StudyMark Schiffman, Andrew G Glass, Nicolas Wentzensen, et al.Pageof 10